| Dr Amardeep Dhaliwal, MD | |
|
10803 Se Kent Kangley Rd Ste 103, Kent, WA 98030-7194 | |
| (206) 800-3445 | |
| (206) 485-2946 |
| Full Name | Dr Amardeep Dhaliwal |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 8 Years |
| Location | 10803 Se Kent Kangley Rd Ste 103, Kent, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568826949 | NPI | - | NPPES |
| 2258765 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD61316125 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Raj K. Singla M.d.p.a. | 7911803515 | 2 |
News Archive
The Endocrine Society presented U.S. Senate Assistant Majority Leader Dick Durbin (D-IL) with the Biomedical Research Champion Award during a ceremony today at its annual meeting.
As part of their long-term investigation of regulatory factors in the bacterial cell cycle, molecular biologists at the University of Massachusetts Amherst now report finding a surprising new role for one factor, CpdR, an adaptor that helps to regulate selective protein destruction, the main control mechanism of cell cycle progression in bacteria, at specific times.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Although some states would see claims costs decline, the study by the Society of Actuaries forecasts that a majority will experience double-digit increases in the individual health insurance market. Officials in some states disputed the analysis, saying it was based on flawed data.
› Verified 8 days ago
| Entity Name | Raj K. Singla M.d.p.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003984873 PECOS PAC ID: 7911803515 Enrollment ID: O20031212000049 |
News Archive
The Endocrine Society presented U.S. Senate Assistant Majority Leader Dick Durbin (D-IL) with the Biomedical Research Champion Award during a ceremony today at its annual meeting.
As part of their long-term investigation of regulatory factors in the bacterial cell cycle, molecular biologists at the University of Massachusetts Amherst now report finding a surprising new role for one factor, CpdR, an adaptor that helps to regulate selective protein destruction, the main control mechanism of cell cycle progression in bacteria, at specific times.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Although some states would see claims costs decline, the study by the Society of Actuaries forecasts that a majority will experience double-digit increases in the individual health insurance market. Officials in some states disputed the analysis, saying it was based on flawed data.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amardeep Dhaliwal, MD 10803 Se Kent Kangley Rd Ste 103, Kent, WA 98030-7194 Ph: (206) 800-3445 | Dr Amardeep Dhaliwal, MD 10803 Se Kent Kangley Rd Ste 103, Kent, WA 98030-7194 Ph: (206) 800-3445 |
News Archive
The Endocrine Society presented U.S. Senate Assistant Majority Leader Dick Durbin (D-IL) with the Biomedical Research Champion Award during a ceremony today at its annual meeting.
As part of their long-term investigation of regulatory factors in the bacterial cell cycle, molecular biologists at the University of Massachusetts Amherst now report finding a surprising new role for one factor, CpdR, an adaptor that helps to regulate selective protein destruction, the main control mechanism of cell cycle progression in bacteria, at specific times.
Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.
Although some states would see claims costs decline, the study by the Society of Actuaries forecasts that a majority will experience double-digit increases in the individual health insurance market. Officials in some states disputed the analysis, saying it was based on flawed data.
› Verified 8 days ago
Dr. Yicheng Chen, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 321 Ramsay Way Ste 107, Kent, WA 98032 Phone: 206-215-3850 Fax: 206-215-3870 | |
Craig M Young, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 24020 132nd Ave Se, Kent, WA 98042 Phone: 253-631-2929 Fax: 253-631-2972 |